2.37 USD
▲-0.05+2.16%
2026-08-03
市值
$190.95M
市盈率
12.27
EPS
0.19
股息率
—
52 周区间
1.42 – 3.19
成交量
716.16K
Beta
-0.00
目标价
11.00
52W 低 1.4252W 高 3.19
价格走势
公司简介
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell...